This archive contains the following articles listed by volume, issue and page number:
 |
|
|
Volume 11, 2007 Articles |
Title (Click for Details) |
Vol/Issue |
Page |
PreScription: IJPC: The Next 10 Years |
Vol. 11 No. 1 |
2 |
Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development—Pediatric Formulations Initiative, Part 1 |
Vol. 11 No. 1 |
5 |
Principles of Pediatric Palliative Care and Pain Control |
Vol. 11 No. 1 |
10 |
Pediatric Oral Formulations: A Continual Challenge |
Vol. 11 No. 1 |
17 |
Sevelamer Suspension in Children with End-Stage Renal Disease |
Vol. 11 No. 1 |
20 |
Case Report: Cocktail Dosing in a Premature Infant with a History of Cholestasis |
Vol. 11 No. 1 |
26 |
Case Report: Treatment of Labial Adhesions in a Child |
Vol. 11 No. 1 |
27 |
Compounding In Crisis:The Aftermath of Hurricane Katrina |
Vol. 11 No. 1 |
28 |
Information Resources and Software for the Hospital Compounding Pharmacist |
Vol. 11 No. 1 |
36 |
Psychotropic Medications in the Treatment of Feline Urine Spraying |
Vol. 11 No. 1 |
44 |
Basics of Compounding for Hazardous Drugs, Part 3: Safe Handling and Personal Protection |
Vol. 11 No. 1 |
50 |
Quality Control Analytical Methods: The Quality of Sterility Testing |
Vol. 11 No. 1 |
52 |
Collaborative Drug Therapy Management and its Application to Pharmaceutical Compounding |
Vol. 11 No. 1 |
56 |
Pharmacogenomics: The End of Trial-and-Error Medicine? |
Vol. 11 No. 1 |
59 |
Standard Operating Procedure: Refrigerator—Installation,Maintenance, Cleaning, and Power Interruptions |
Vol. 11 No. 1 |
66 |
Calculations |
Vol. 11 No. 1 |
68 |
Caffeine Citrate 10-mg/mL Oral Liquid |
Vol. 11 No. 1 |
69 |
Carbidopa 1.25-mg/mL Oral Liquid |
Vol. 11 No. 1 |
70 |
Clonidine Hydrochloride 0.1-mg/mL Oral Liquid |
Vol. 11 No. 1 |
71 |
Dexamethasone 1-mg/mL Oral Liquid |
Vol. 11 No. 1 |
72 |
Fluoxetine Hydrochloride 1-mg/mL Oral Liquid |
Vol. 11 No. 1 |
73 |
Lansoprazole 3-mg/mL Oral Liquid |
Vol. 11 No. 1 |
74 |
Methyldopa 25-mg/mL Oral Liquid |
Vol. 11 No. 1 |
75 |
Metolazone 1-mg/mL Oral Liquid |
Vol. 11 No. 1 |
76 |
Prednisone 10-mg/mL Oral Liquid |
Vol. 11 No. 1 |
77 |
Prednisolone Sodium Phosphate 10-mg/mL Oral Liquid |
Vol. 11 No. 1 |
78 |
Chemical Stability of Desonide in Ear Drops |
Vol. 11 No. 1 |
79 |
Physical and Chemical Stability of Palonosetron with Metoclopramide and Promethazine During Simulated Y-Site Administration |
Vol. 11 No. 1 |
82 |
PostScription: IJPC—More Than a Journal |
Vol. 11 No. 1 |
88 |
PreScription: Putting the Science Back into Pharmacy |
Vol. 11 No. 2 |
92 |
Insulins: Historical and Current Perspectives |
Vol. 11 No. 2 |
95 |
Compounding for the Complications of Diabetes: Interviews with Compounding Pharmacists George B. Muller, RPh, and Jerrod Roberts, DPh |
Vol. 11 No. 2 |
106 |
Certified Diabetes Educator: A Credential for Compounding Pharmacists |
Vol. 11 No. 2 |
112 |
Challenges of Compounding for Patients on the Ketogenic Diet |
Vol. 11 No. 2 |
116 |
Compounded Treatments for Erectile Dysfunction: A Common Complication of Diabetes |
Vol. 11 No. 2 |
122 |
Including Pets in Diabetic Care |
Vol. 11 No. 2 |
126 |
Case Report: Shingles Triple Cream in the Treatment of Herpes Zoster |
Vol. 11 No. 2 |
131 |
Innovative Uses of Compounded Tranilast: An Interview with Compounding Pharmacist Larry J. Frieders, RPh |
Vol. 11 No. 2 |
132 |
Records and Record-Keeping for the Hospital Compounding Pharmacist |
Vol. 11 No. 2 |
138 |
Quality Control Analytical Methods: Considerations in Compounding Peroral Solid Dosage Forms |
Vol. 11 No. 2 |
145 |
Basics of Compounding for Hazardous Drugs, Part 4: Developing the Hazardous Drugs List and Containment Workstations |
Vol. 11 No. 2 |
149 |
Calculations |
Vol. 11 No. 2 |
152 |
Standard Operating Procedure: Discarding of Broken Glass |
Vol. 11 No. 2 |
153 |
Aspirin 80-mg/5-mL Oral Liquid, Anhydrous |
Vol. 11 No. 2 |
154 |
Busulfan 2-mg/mL Oral Liquid |
Vol. 11 No. 2 |
155 |
Cefuroxime Axetil 10-mg/mL Oral Liquid |
Vol. 11 No. 2 |
156 |
Metformin Hydrochloride 100-mg/mL Oral Liquid |
Vol. 11 No. 2 |
157 |
Ondansetron Hydrochloride 0.8mg/mL Oral Liquid |
Vol. 11 No. 2 |
158 |
Oral Liquid Vehicle, Anhydrous |
Vol. 11 No. 2 |
159 |
Phenoxybenzamine Hydrochloride 2-mg/mL Oral Liquid |
Vol. 11 No. 2 |
160 |
Ranitidine Hydrochloride 15-mg/mL Oral Liquid |
Vol. 11 No. 2 |
161 |
Tegaserod Meleate 0.1-mg/mL Oral Liquid |
Vol. 11 No. 2 |
162 |
Triprolidine Hydrochloride 0.25-mg/mL Syrup |
Vol. 11 No. 2 |
163 |
Stability of Oseltamivir in Various Extemporaneous Liquid Preparations |
Vol. 11 No. 2 |
164 |
PostScription: Responsibility: A Critical Aspect of Compounding Pharmacy |
Vol. 11 No. 2 |
178 |
PreScription: State or Federal Control of Pharmacy Practice |
Vol. 11 No. 3 |
178 |
Transdermal Gel in the Treatment of Postoperative Pain |
Vol. 11 No. 3 |
181 |
Oral Methadone for Management of Regional Sympathetic Dystrophy Syndrome: A Case Revisited |
Vol. 11 No. 3 |
187 |
The Rectal Rocket: A Two-Day Treatment for Hemorrhoids |
Vol. 11 No. 3 |
194 |
Case Report: Ketoprofen/Riboflavin/Caffeine Capsules and Progesterone Therapy for Recurrent Migraine Pain |
Vol. 11 No. 3 |
200 |
Levorphanol for the Treatment of Severe Chronic Pain |
Vol. 11 No. 3 |
202 |
Levorphanol for Excruciating Pain from Oral Cancer: A Case Report |
Vol. 11 No. 3 |
212 |
Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2 |
Vol. 11 No. 3 |
220 |
Quality Control: Standard Operating Procedures--An Essential Tool for Developing Quality Preparations |
Vol. 11 No. 3 |
226 |
Basics of Compounding for the Implementation of United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 1 |
Vol. 11 No. 3 |
230 |
Calculations - Compounding for Pain Management |
Vol. 11 No. 3 |
238 |
Standard Operating Procedure: Basic Compounding Documentation--the Master Formula Form |
Vol. 11 No. 3 |
240 |
Benazepril 2-mg/mL Oral Liquid |
Vol. 11 No. 3 |
242 |
Cholecalciferol 40,000-IU/mL Oral Liquid |
Vol. 11 No. 3 |
243 |
Folic Acid 1-mg/mL Oral Liquid |
Vol. 11 No. 3 |
244 |
Glycopyrrolate 0.5-mg/mL Oral Liquid |
Vol. 11 No. 3 |
245 |
Isoproterenol Compound Elixir |
Vol. 11 No. 3 |
246 |
Levothyroxine Sodium 40-micro-g/mL Oral Liquid |
Vol. 11 No. 3 |
247 |
Losartan Potassium 2.5-mg/mL Oral Liquid |
Vol. 11 No. 3 |
248 |
Methylphenidate 1-mg/mL Oral Liquid |
Vol. 11 No. 3 |
249 |
Thiamine Hydrochloride 100-mg/mL Oral Liquid |
Vol. 11 No. 3 |
250 |
Trovafloxacin Mesylate 10-mg/mL Oral Liquid |
Vol. 11 No. 3 |
251 |
Rheologic Profile, Specific Gravity, Surface Tension, and pH of Fifteen Over-the-Counter Preparations |
Vol. 11 No. 3 |
252 |
Chemical Stability of Hydrocortisone in an Oral Liquid Dosage Form without Suspending Agents |
Vol. 11 No. 3 |
259 |
PostScription: Lobbying: How It Affects Compounding |
Vol. 11 No. 3 |
262 |
PreScription: Bias, NAMS, and HRT |
Vol. 11 No. 4 |
266 |
Correcting Misconceptions about Compounding Bioidentical Hormones: A Review of the Literature |
Vol. 11 No. 4 |
269 |
The History of Progesterone |
Vol. 11 No. 4 |
274 |
The Politics of Hormone Replacement Therapy |
Vol. 11 No. 4 |
278 |
Premarin: The Intriguing History of a Controversial Drug |
Vol. 11 No. 4 |
282 |
Common Acronyms Used by Health Professionals Who Prescribe or Prepare Hormone Replacement |
Vol. 11 No. 4 |
288 |
The Lived Experience of Perimenopausal and Menopausal Women Undergoing Treatment with Bioidentical Hormones |
Vol. 11 No. 4 |
292 |
Obtaining Accreditation by the Pharmacy Compounding Accreditation Board, Part 1: An Overview |
Vol. 11 No. 4 |
297 |
Book Review: The Rexall Story: A History of Genius and Neglect |
Vol. 11 No. 4 |
300 |
Update on the Proposed Revision Process for United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations |
Vol. 11 No. 4 |
302 |
Quality-control Analytical Methods: Logbooks and Documentation Forms |
Vol. 11 No. 4 |
306 |
Basics of Compounding: The Responsibilities of Compounding Personnel in Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 2 |
Vol. 11 No. 4 |
314 |
Calculations |
Vol. 11 No. 4 |
324 |
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration |
Vol. 11 No. 4 |
326 |
Fentanyl 50-mg/mL in 0.9% Sodium Chloride Solution |
Vol. 11 No. 4 |
328 |
Ketoconazole 25-mg Liquid Suppository |
Vol. 11 No. 4 |
329 |
Mebeverine Hydrochloride 20% gel |
Vol. 11 No. 4 |
330 |
Moxifloxacin in Dianeal 1.36% Peritoneal Dialysis Solution |
Vol. 11 No. 4 |
331 |
Oseltamivir 12-mg/mL Oral Suspension |
Vol. 11 No. 4 |
332 |
Phenytoin Sodium 20-mg/mL Topical Suspension |
Vol. 11 No. 4 |
333 |
Ribavirin 40-mg/mL Suspension |
Vol. 11 No. 4 |
334 |
Sufentanil 50-mg/mL in 0.9% Sodium Chloride Solution |
Vol. 11 No. 4 |
335 |
Temozolomide 10-mg/mL Oral Liquid |
Vol. 11 No. 4 |
336 |
Vehicle N Formulas |
Vol. 11 No. 4 |
337 |
Statistical Analysis of Barrier Isolator/Glovebox Glove Failure |
Vol. 11 No. 4 |
338 |
Chemical Stability of Cyproheptadine Hydrochloride in an Oral Liquid Dosage Form |
Vol. 11 No. 4 |
347 |
PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1 |
Vol. 11 No. 4 |
350 |
PreScription: Pharmacy Education: Is It Contemporary? |
Vol. 11 No. 5 |
354 |
United States Pharmacopeia Convention Standards and Clinical Information for Compounded Medications Used in Veterinary Medicine |
Vol. 11 No. 5 |
357 |
Rabbit Medicine |
Vol. 11 No. 5 |
364 |
The Whales: A Pharmacist's Story |
Vol. 11 No. 5 |
376 |
Equine Cushing's Disease: A Clinical Update |
Vol. 11 No. 5 |
384 |
Submitting Compelling Case Reports for Drug Therapy in Veterinary Patients |
Vol. 11 No. 5 |
390 |
Obtaining Accreditation by the Pharmacy Compounding Accreditation Board, Part 2: Developing Essential Standard Operating Procedures |
Vol. 11 No. 5 |
397 |
Quality-Control Analytical Methods: A Discussion of United States Pharmacopeia Chapter <71> Sterility Tests |
Vol. 11 No. 5 |
400 |
Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 3: Risk Levels |
Vol. 11 No. 5 |
404 |
Calculations: Compounding for Veterinary Patients |
Vol. 11 No. 5 |
412 |
Standard Operating Procedure: Complaint and Mishap Rectification |
Vol. 11 No. 5 |
414 |
Acetaminophen 500-mg and Diphenhydramine Hydrochloride 25-mg Hot Therapy Packs |
Vol. 11 No. 5 |
416 |
Acetylcysteine 200-mg/mL Oral Liquid |
Vol. 11 No. 5 |
417 |
Acetylcysteine 200-mg Packets |
Vol. 11 No. 5 |
418 |
Betamethasone Valerate 0.1% Topical Gel |
Vol. 11 No. 5 |
419 |
Dexpanthenol 5% Gel-Cream |
Vol. 11 No. 5 |
420 |
Diclofenac Sodium 75-mg/mL Injection |
Vol. 11 No. 5 |
421 |
Ergonovine Maleate 0.2-mg/mL Injection, Veterinary |
Vol. 11 No. 5 |
422 |
Hydrocortisone 0.5% Ethanolic Gel |
Vol. 11 No. 5 |
423 |
Neomycin 0.05% Topical Gel |
Vol. 11 No. 5 |
424 |
Nondetergent Neutral Dry Skin Cream |
Vol. 11 No. 5 |
425 |
Zinc Content of Commercial Diluents Widely Use in Drug Admixtures Prepared for Intravenous Infusion |
Vol. 11 No. 5 |
426 |
Isoniazid Release from Suppositories Compounded with Selected Bases |
Vol. 11 No. 5 |
433 |
PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 2 |
Vol. 11 No. 5 |
438 |
PreScription: Thoughts on Technology and Pharmacy |
Vol. 11 No. 6 |
442 |
The Internet on Steroids: How Connected is Your Pharmacy? |
Vol. 11 No. 6 |
445 |
Achievement of USP Chapter <797> Compliance by a 35-Bed Rural Hospital: A Case Study |
Vol. 11 No. 6 |
450 |
The Internet and Its Websites: Your New Business Partner |
Vol. 11 No. 6 |
472 |
Proteins Used as Sweeteners |
Vol. 11 No. 6 |
476 |
Soda Jerk |
Vol. 11 No. 6 |
483 |
Quality-Control Analytical Methods: In-House Quality Control of Simple Compounds |
Vol. 11 No. 6 |
487 |
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 4: Considerations in Selection and Use of Disinfectants and Antiseptics |
Vol. 11 No. 6 |
492 |
Calculations: High-Technology Compounding and Investigational Dispensing |
Vol. 11 No. 6 |
500 |
Standard Operating Procedure: Vial Crimper--Use, Care, Cleaning, and Maintenance |
Vol. 11 No. 6 |
502 |
Aloe Vera Gel |
Vol. 11 No. 6 |
504 |
Breast Care Cream |
Vol. 11 No. 6 |
505 |
Castor Oil and Trypsin Ointment |
Vol. 11 No. 6 |
506 |
Chlorhexidine 2% Gel |
Vol. 11 No. 6 |
507 |
Coal Tar 2% and Allantoin 2.5% Cream |
Vol. 11 No. 6 |
508 |
Foscarnet 2.5% Topical Cream |
Vol. 11 No. 6 |
509 |
Interferon alfa-2b Ophthalmic Solution |
Vol. 11 No. 6 |
510 |
Lidocaine Hydrochloride 1.82% Buffered Injection |
Vol. 11 No. 6 |
511 |
Miconazole 2% Oral Gel |
Vol. 11 No. 6 |
512 |
Sodium Phenylbutyrate 200-mg/mL Oral Liquid |
Vol. 11 No. 6 |
513 |
Topical Pain Relief: Assessment of Patient Satisfaction with a Novel Compound Containing at Least Ketoprofen |
Vol. 11 No. 6 |
514 |
Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration |
Vol. 11 No. 6 |
520 |
PostScription: The History of Pharmacy |
Vol. 11 No. 6 |
526 |